New Patent Rules Pit Wall Street Against Big Pharma

Hedge funds have found a new way to make money: challenge a pharma company?s patent on a specific drug and then make a killing as they short the stock and the share price goes weak in the knees. But the long-term prognosis for this strategy is far from clear, as drug companies seek to close the regulatory opportunity they accuse hedge funds of abusing.